Table 1

	MTX (n=58); 131.6 PY	ETA (n=143); 355.8 PY	RR (95% CI)	TOC (n=72); 111.6 PY	RR (95% CI)	IL-1i (n=55); 116.8 PY	RR (95% CI)

AE (Rate/PY)	30 (0.23)	71 (0.20)	0,88 (0,57–1,34)	118 (1.06)	4,64 (3.11–6.92)****	81 (0.69)	3.04 (2.0–4.,62)****
SAE (Rate/PY)	3 (0.02)	18 (0.05)	2.22 (0.65–7.53)	14 (0.13)	5.5 (1.58–19.1)**	17 (0.15)	6.39 (1,87–21.8)**
JIA-Reactivation, N (Rate/PY)	1 (0.01)	4 (0.01)	1.48 (0.17–13.2)	7 (0.06)	8.25 (1.01–67.1)*	10 (0.86)	11,3 (1.44–88.0)*
MAS; n (Rate/PY)	2 (0.02)	3 (0.01)	0.12 (0.01–1.18)	5 (0.05)	2.95 (0.57–15.2)	3 (0.03)	1.69 (0.28–10.1)
Hypersensitivity; n (Rate/PY)	1 (0.01)	5 (0.01)	1.85 (0.22–15.8)	4 (0.04)	4.72 (0.52–42.3)	2 (0.02)	2.25 (0.20–24.9)
Infections, N (Rate/PY)	15 (0.12)	16 (0.05)	0.39 (0.20–0.80)**	55 (0.49)	4.3 (2.44–7.65)****	39 (0.33)	2.93 (1.62–5.31)***